Editorial: UK private drug payments – a can of worms for the pharma industry
This article was originally published in Scrip
Last week Alan Johnson, the UK's health secretary, sparked controversy after announcing that National Health Servicepatients would be able to buy medicines privately without forfeiting their right to state-funded treatment.
You may also be interested in...
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.